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Key Points
• Regadenoson did not
reduce iNKT cell acti-
vation to a prespecified
level when adminis-








Adenosine A2A receptor (A2AR) agonists have been shown to decrease tissue inﬂammation
induced by hypoxia/reoxygenation in mice with sickle cell disease (SCD). The key mediator
of the A2AR agonist’s anti-inﬂammatory effects is a minor lymphocyte subset, invariant
natural killer T (iNKT) cells. We tested the hypothesis that administration of an A2AR
agonist in patients with SCD would decrease iNKT cell activation and dampen the severity of
vaso-occlusive (VO) crises. In a phase 2, randomized, placebo-controlled trial, we
administered a 48-hour infusion of the A2AR agonist regadenoson (1.44 mg/kg per hour) to
patients with SCD during VO crises to produce a plasma concentration of ;5 nM, a
concentration known from prior studies to suppress iNKT cell activation in SCD. The
primary outcome measure was a .30% reduction in the percentage of activated iNKT cells.
Ninety-two patients with SCD were randomized to receive a 48-hour infusion of
regadenoson or placebo, in addition to standard-of-care treatment, during hospital
admission for a VO crisis and had analyzable iNKT cell samples. The proportion of subjects
who demonstrated a reduction of .30% in activated iNKT cells was not signiﬁcantly
different between the regadenoson and placebo arms (43% vs 23%; P5 .07). There were also
no differences between regadenoson and placebo groups in length of hospital stay, mean
total opioid use, or pain scores. These data demonstrate that a low-dose infusion of
regadenoson intended to reduce the activity of iNKT cells is not suﬃcient to produce a
statistically signiﬁcant reduction in such activation or in measures of clinical eﬃcacy. This
trial was registered at www.clinicaltrials.gov as #NCT01788631.
Introduction
Invariant natural killer T (iNKT) cells are implicated in the pathogenesis of sickle cell disease (SCD).1-3 In
patients with SCD, iNKT cells are increased in number and activation state compared with controls.1 In a
SCD mouse model, depletion of iNKT cells or blockage of their activation reduced pulmonary
inflammation and injury.1,2 One strategy used to decrease iNKT cell activation in SCD mice was
treatment with a selective adenosine A2A receptor (A2AR) agonist.
2 Based on these data, we previously
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conducted a phase 1 study of the A2AR agonist, regadenoson, in
adults with SCD.3 In that study, we established a safe and effective
infusion schedule for regadenoson (1.44 mg/kg per hour) that
produced a steady-state plasma level of 5 nM and appeared to
depress the activity of iNKT cells in SCD patients during a vaso-
occlusive (VO) crisis. Although no dose-limiting toxicity was noted,
we decided not to examine higher infusion rates to avoid the side
effects that are commonly observed during myocardial imaging
when regadenoson is administered as a bolus, which achieves a
plasma concentration of ;16 nM,4 and because the cost of higher
doses would be prohibitive.
The current study is a phase 2, multicenter, randomized, placebo-
controlled trial of regadenoson to determine its efficacy for the
treatment of an acute, VO episode. A 48-hour continuous infusion
of 1.44 mg/kg per hour regadenoson or placebo was administered
to determine whether the drug could decrease the percentage of
highly activated iNKT cells, as measured by binding of a fluorescent
antibody to the 65-kDa subunit of NF-kB phosphorylated on serine
536 (pNF-kB), and decrease the severity of VO crises, as measured




A phase 2, multicenter, double-blinded, randomized, placebo-
controlled trial of regadenoson was conducted in children and
adults with sickle cell anemia (HbSS/HbSb0-thalassemia), 10 to 60
years of age, who were admitted to the hospital for an acute VO
crisis (see supplemental Methods for specific inclusion/exclusion
criteria). Patients were randomized using a permuted blocks
algorithm for each participating site. Treatment was assigned
centrally by registrars in the Office of Data Quality at the Dana-
Farber Cancer Institute, with unblinded assignment transferred only
to the investigational pharmacy at the treating institution. No
treatment assignment was unblinded during the trial. After
randomization, infusional regadenoson (1.44 mg/kg per hour) or
placebo was started within 36 hours of the first dose of parenteral
opioids and continued for 48 hours. A 36-hour window was
selected, as opposed to 24 hours, to facilitate accrual; a 48-hour
infusion was selected, as opposed to 24 hours as was done in
phase 1, in order to have a more significant clinical effect on inflam-
mation. The primary outcome measure was a .30% decrease in
the percentage of circulating iNKT cells expressing high levels of
pNF-kB at 48 hours compared with predrug levels. Secondary
outcome measures were: length of hospital stay, parenteral opioid
use, visual analog pain scale, and composite respiratory score,
defined as: (1) respiratory rate decreased by 25% from baseline or
normalized (#20 bpm) or (2) degree of hypoxia (SpO2) on room
air increased by 10% from baseline or normalized ($92%) or
(3) thoracic pain improved by 3 points from baseline on a 10-point
visual analog scale. If subjects experienced any of these outcomes,
they were classified as having an improvement in respiratory
symptoms. The trial was performed at 9 collaborating hospitals (see
supplemental Methods for participating sites); blood samples were
shipped to a central laboratory in La Jolla, CA, at 4°C to 6°C for the
performance of flow cytometry. Institutional review boards approved
the study protocol at participating sites, and informed consent was
obtained from all participants.
Laboratory methodology
iNKT cells were identified by flow cytometry as live, CD192
(SJ25-C1; Invitrogen), CD31 (UCHT1; Invitrogen and BD Biosci-
ences), and Va24-Ja18 TCR1 (6B11; eBioscience) cells.
Conventional T cells were identified as live, CD192, CD31,




































Figure 1. Subject flow through the study.
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NF-kB was identified with anti-pNF-kB (Ser536, 93H1; Cell
Signaling Technology).
To determine the activation state of iNKT cells, we measured by
flow cytometry their expression of pNF-kB relative to conventional
CD31 T cells, which are minimally activated by VO. The lower
boundaries of activation gates were set to exclude expression levels of
95% of conventional CD31 T cells. The data were expressed as the
percentage of iNKT cells in the activation gate and were reproducible
when repeated on different days in steady-state patients.
Statistical analysis
For data analysis, to achieve a 30% reduction in pNF-kB–activated
iNKT cells at 48 hours, compared with predrug levels, 100 subjects (50
in each arm) provide 80% power to distinguish a 50% success rate in
the regadenoson arm comparedwith a 20%success rate in the placebo
arm, using a 2-sided test with an a of 0.05. Although we hypothesized
that regadenoson treatment would decrease pNF-kB activation, we
nevertheless chose to evaluate the data using a 2-sided analysis.
Laboratory results were analyzed with robust methods (median, range).
Comparisons of pNF-kB parameters between placebo and regade-
noson arms pretreatment and during treatment were performed. The
2-sided Fisher exact test or theWilcoxon rank sum test, as appropriate,
was used to compare randomized treatment groups. Analysis of
iNKT cell activation markers was reported as the percentage change
from the value at time 0 to the value at 48 hours from the start of the
infusion ([% time 02% time 48 hours]/% time 0). If a 48-hour sample
was not available, a 24-hour sample was substituted.
Results
Four thousand nine hundred forty hospital admissions were screened
in order to enroll and randomize 100 subjects with HbSS/HbSb0-
thalassemia, 53 to the regadenoson arm and 47 to the placebo arm
(Figure 1; Table 1). Ninety-two subjects were treated and provided
blood samples for the assessment of the primary end point. There
were no differences in age, sex, or hydroxyurea use between the
regadenoson and placebo group. The majority of patients were
adults, and most were prescribed hydroxyurea. Study enrollment
began in June 2012 and ended in November 2016.
There was no significant effect of 5 nM regadenoson on pNF-kB
iNKT cell activation. When expressed as percentage of baseline,
median end-of-study (48 hours) pNF-kB iNKT cell activation was
only modestly reduced compared with baseline (pretreatment)
levels for both the regadenoson (7.5% reduction) and placebo
groups (1.3% reduction). And, although there was a trend, there
was also not a significant difference in the primary outcome
measure, a.30% reduction of pNF-kB p65-activated iNKT cells at
48 hours compared with baseline. In the regadenoson and placebo
arms, respectively, 21 of 49 (42.9%) and 10 of 43 (23.3%)
experienced such a reduction (P 5 .07) (Figure 2).
Differences in measures of clinical efficacy were not detected. Median
length of hospital stay was similar in both arms (3.96 days vs 3.99 days;
P5 .80). There was also no difference between the regadenoson and
placebo arms in the amount of parenteral opioids used during infusion
(medianmorphine equivalent dose, 0.03mg/kg per hour vs 0.04mg/kg
per hour; P5 .34), mean reduction in visual analog pain score (22.68
vs 22.80; P 5 .91), or improvement in composite respiratory score
(20.83% vs 21.43%; P5 1.0). When we compared clinical outcomes
within the regadenoson arm between those who did and did not
respond (48-hour pNF-kB iNKT cells with a decline of .30% from
baseline), there were no differences in length of stay (4.41 days vs 3.74
days; P 5 .47), amount of parenteral opioids used during infusion
(medianmorphine equivalent dose, 0.04mg/kg per hour vs 0.03mg/kg
per hour; P5 .63), mean reduction in visual analog pain score (22.80
vs 22.67; P 5 .86), or improvement in composite respiratory score
(26.67% vs 18.33%; P 5 .42).
Finally, regadenoson was not associated with an increased rate of
adverse events or serious adverse events, including alterations to
blood pressure and heart rate (see supplemental Table 1).
Discussion
This study did not achieve its primary outcome measure of a




















Figure 2. Baseline vs end-of-infusion p65-phospho NF-kB iNKT cell
activation. Points below the black line represent patients who achieved the primary
outcome measure of a p65-phospho-NF-kB iNKT cell activation at 48 hours that
was a .30% reduction from baseline. Subjects in the regadenoson and placebo
arms are represented by red and white circles, respectively.
Table 1. Demographics and medications by treatment arm
Regadenoson, n 5 53 Placebo, n 5 47 P
Age, median (range), y 25 (10-54) 26 (13-56) .29
Pediatric, ,18 y (%) 6 (11) 8 (17) .57
Sex (%) .42
Female 22 (42) 24 (51)
Male 31 (58) 23 (49)
Race (%) 1.0
Black or African American 49 (92) 44 (94)
Other 4 (8) 3 (6)
Currently taking hydroxyurea (%) 38 (72) 33 (70) 1.0
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compared with placebo. We also did not observe an improvement in
clinical outcomes and, because we examined several measures of clinical
efficacy, the likelihood we falsely accepted the null hypothesis is low.
Obviously, one reason for the negative result is that the null hypothesis is
true and regadenoson does not have a significant effect on iNKT cell
activation or clinical outcomes. There are other potential explanations,
however, as to why we did not see a biological or clinical response.
The dose of regadenoson used in our trial may have been too low to
reduce iNKT cell activation. For its US Food and Drug Admin-
istration (FDA)-indicated use during myocardial stress imaging,
regadenoson is administered as a 400-mg bolus, achieving peak
plasma concentrations of;16 nM and then redistributing over time
to lower levels.5 Potential side effects are hypotension, reflex
tachycardia, flushing, and bronchospasm. Because we would be
administering regadenoson during a VO crisis, we were concerned
about the effect of these toxicities on an already-ill patient. Other
challenges were regadenoson’s 5-minute half-life, which necessi-
tated that we delivered it as a continuous infusion in order to
decrease the severity of a VO crisis and cost.6 A dose was chosen
that appeared to maximize the effect on iNKT cells, while minimizing
toxicities and not being cost prohibitive. In the phase 1 study, we
extrapolated the target dose, 1.44 mg/kg per hour, from animal
studies.2,7 Using this dose, we achieved peak plasma concentra-
tions of ;5 nM, or about one-third of the concentrations seen in
stress imaging,3 and encountered no dose-limiting side effects.3
Still, in the 6 patients who received regadenoson infusion for
24 hours in the phase 1 study, there was 50% median reduction in
the fraction of circulating pNF-kB–high iNKT cells. On the basis of
these data, we concluded that the drug concentration (1.44 mg/kg
per hour, resulting in 5 nM steady-state plasma regadenoson
concentration) was sufficient to strongly inhibit iNKT cells. It is
possible that we might have attained a more significant effect on
iNKT cell activation, while still avoiding unwanted side effects, if we
had used a higher infusional dose of regadenoson.
A reduction in activated circulating iNKT cells could be the result of a
drug effect or the exodus of activated cells from the circulation. In the
current study, we found that 23% of patients who received placebo
for 48 hours during VO crisis displayed a 30% or greater reduction in
the fraction of activated circulating iNKT cells. A possible explanation
for this reduction in circulating activated iNKT cells during VOmay be
that many activated iNKT cells extravasate into inflamed tissues or
become adhered to activated endothelial cells during VO.
Treatment of a VO crisis is likely more challenging than prevention.
Regadenoson’s short half-life and low oral bioavailability necessitated
that it be administered as an infusion during a VO crisis.5 By the time
a patient with SCD presents to the hospital for pain, the VO crisis
has likely been ongoing for days, with the pathogenesis of VO
already widespread. Historically, therapeutic approaches to atten-
uate this process have been unsuccessful,8,9 whereas there have
been successful approaches to prevent VO, such as transfusion,10
hydroxyurea,11 and crizanlizumab.12
Despite murine data suggesting that iNKT cells are critical to the
initiation and propagation of VO,1,2,13 we found that a 48-hour
infusion of regadenoson did not significantly decrease pNF-kB
iNKT cell activation, or the severity of VO crises, in patients with
SCD. Although a higher dose may have provided benefit, further
studies of single-agent regadenoson for the management of VO are
probably not worth the investment. A better approach, and one that
is similar to the crizanlizumab strategy, may be the long-term
depletion of iNKT cells with a monoclonal antibody, such as
NKTT120, aimed to prevent VO crises.14 Alternatively, iNKT cells
may not play a significant role in VO in humans.
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